Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Mantle Cell Lymphoma

Mantle Cell Lymphoma

Part of Non-Hodgkin's Lymphoma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Mantle Cell Lymphoma

148 trials tracked for Mantle Cell Lymphoma: 10 in phase 3 or 4 and 5 with published results. The most-cited published study has 462 citations.

148Trials tracked
10Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 1 Phase 3 9 Phase 2 118 Phase 1 12 Other / NA 8
  1. Phase 3 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed · 462 cited
  2. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Completed · 210 cited
  3. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 111 cited
  4. Phase 3 Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) Completed · 49 cited
  5. Phase 3 Double Cord Versus Haploidentical (BMT CTN 1101) Completed · 10 cited
  6. Phase 4 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Completed
Show 44 more trials
  1. Phase 3 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study Completed
  2. Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Completed
  3. Phase 3 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed
  4. Phase 3 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed
  5. Phase 2 A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma Completed
  6. Phase 2 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Completed
  7. Phase 2 Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Completed
  8. Phase 2 A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Completed
  9. Phase 2 Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma Completed
  10. Phase 2 Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed
  11. Phase 2 A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) Completed
  12. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
  13. Phase 2 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Completed
  14. Phase 2 A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) Completed
  15. Phase 2 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Completed
  16. Phase 2 Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma Completed
  17. Phase 2 Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma Completed
  18. Phase 2 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Completed
  19. Phase 2 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Completed
  20. Phase 2 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Completed
  21. Phase 2 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma Completed
  22. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  23. Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) Completed
  24. Phase 2 VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma Completed
  25. Phase 2 CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed
  26. Phase 2 Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Completed
  27. Phase 2 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Completed
  28. Phase 2 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma Completed
  29. Phase 2 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma Completed
  30. Phase 2 A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial Completed
  31. Phase 2 Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) Completed
  32. Phase 2 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Completed
  33. Phase 2 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed
  34. Phase 2 Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma Completed
  35. Phase 2 Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy Completed
  36. Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed
  37. Phase 2 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed
  38. Phase 2 Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Completed
  39. Phase 2 Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell Completed
  40. Phase 2 Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Completed
  41. Phase 2 Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma Completed
  42. Phase 2 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
  43. Phase 2 Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Completed
  44. Phase 2 EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma Completed

Showing the 50 most-cited and recently-updated of 148 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Mantle Cell Lymphoma: what the trials found

Ibrutinib has demonstrated significant improvements in progression-free survival (PFS) and complete response rates in several trials. Specifically, one trial showed a PFS of 15.6 vs 6.2 months (p < 0.0001) 4, while another reported a PFS of 31.9 vs 22.1 months (p = 0.0024) and a complete response rate of 53.7% vs 32.3% (p = 0.0004) 7.

Bendamustine is associated with high overall response rates, ranging from 88.5% to 100% across different study cohorts [5, 12]. One trial showed a significant improvement in PFS with bendamustine (52.9 vs 80.6; p = 0.011) 5, while another reported high overall response rates of 93% to 100% 12.

Rituximab at 375 mg/m^2 showed statistically significant improvements in progression-free survival (437.0 vs 751.0; p < 0.001), time to progression (490.0 vs 929.0; p < 0.001), and time to next anti-lymphoma treatment (756.0 vs 1353.0; p < 0.001) 9.

Fludarabine was associated with a disease-free survival of 70.6% (p = 0.002) and an overall survival of 73.3% in one study 20. Other trials evaluating fludarabine or its combinations showed high overall response rates of up to 97% 11.

Recent results — preliminary, needs further review

  • Lenalidomide demonstrated progression-free survival at 18 weeks ranging from 85.7% to 100% and a 2-year response rate between 66.7% and 100% 1.
  • BeEAM showed an overall survival of 92.3% and 88.6% in a small cohort 14.
  • G-CSF was associated with a 5-year progression-free survival rate of 57.1% and a 5-year overall survival rate of 79.7% 15.

For the clinician treating this condition

  • Ibrutinib is supported by evidence showing significant improvements in both progression-free survival and complete response rates compared to standard controls.
  • Bendamustine consistently achieves high overall response rates (up to 100%) across multiple trials.
  • Rituximab at 375 mg/m^2 significantly extends progression-free survival and time to next anti-lymphoma treatment.
  • Fludarabine is associated with favorable disease-free survival and high overall response rates in established cohorts.

AI synthesis of 10 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Oncology RCT
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
May 16, 2026
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
Oncology FDA Approval
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
FDA May 2, 2026

Research across Non-Hodgkin's Lymphoma

Related studies from across the Non-Hodgkin's Lymphoma family.

Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL
Nutrition & Obesity Medicine Meta-analysis
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL Overweight status linked to better survival in certain lymphoma
A meta-analysis reveals that overweight status correlates with improved survival in DLBCL, while underweight status is linked to poorer clin…
Patients with diffuse large B-cell lymphoma who are overweight may have better survival outcomes than those who are underweight.
Frontiers Jun 24, 2026
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged
Allergy & Immunology Meta-analysis
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged New Treatment Options Show Promise for Specific Lymphoma Patients
This network meta-analysis of 1,016 treatment-naïve patients with MYC/BCL2 double-expressor DLBCL found that Pola-R-CHP significantly reduce…
A new drug combination may reduce the risk of disease progression in patients with a specific type of lymphoma.
Frontiers Jun 23, 2026
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL
Oncology RCT
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL Trial shows new treatment improves progression-free survival for lymphoma
This Phase 3 randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide and R-CHOP in patients with high-ris…
A new drug combination showed improved progression-free survival for patients with high-risk large B-cell lymphoma in a Phase 3 clinical tri…
Jun 20, 2026
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma
Oncology RCT
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma Trial shows lenalidomide and rituximab for advanced follicular lymphoma
This Phase 3 randomized controlled trial of 1030 patients with previously untreated advanced follicular lymphoma found that the combination …
A large trial shows that a combination of two drugs can serve as an effective alternative to chemotherapy for patients with advanced follicu…
Blood Jun 20, 2026
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs
Allergy & Immunology Meta-analysis
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs Organ transplant recipients face higher risk of certain cancers
This meta-analysis of multi-centre cohort and registry-based studies indicates that solid organ transplant recipients experience significant…
People who receive heart or lung transplants face a significantly higher risk of dying from specific types of cancer.
Frontiers Jun 20, 2026
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Hematology Sys. Review
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Frontiers Jun 10, 2026
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Oncology Sys. Review
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Frontiers Jun 2, 2026
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Hematology Meta-analysis
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.
Jun 1, 2026
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
Allergy & Immunology Sys. Review
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …
Frontiers May 29, 2026
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Infectious Disease Meta-analysis
Meta-analysis of double-expressor lymphoma prognoses and novel therapies Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Frontiers May 22, 2026
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
Oncology RCT
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
JAMA May 19, 2026
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
Drug Pipeline Sys. Review
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus CAR-T Trials Show Promise But Face Big Hurdles For Lymphoma Patients
This systematic landscape review of 360 CAR-T cell therapy trials for non-Hodgkin lymphoma found rapid expansion with a predominant focus on…
New research shows that CAR-T cell trials are expanding quickly but scientists must solve big problems like drug resistance before patients …
Frontiers May 9, 2026